164 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug https://www.fool.com/investing/2019/05/09/novo-nordisk-trots-along-waiting-for-its-next-gene.aspx?source=iedfolrf0000001 May 09, 2019 - Oral semaglutide is on its way.
GILD, NVO, ZYNE and NOG among notable after hour movers https://seekingalpha.com/news/3465165-gild-nvo-zyne-nog-among-notable-hour-movers?source=feed_news_all May 17, 2019 - Top Gainers: GILD +3.1%. NOG +3.2%. NBRV +2.7%. GOL +2.3%. NIO +1%.Top Losers: LTM -4.7%. SIGA -1.9%. NKTR -1.8%. NVO -1.7%. ZYNE -1.7%.
Novo Nordisk to Start PIONEER Program on Semaglutide http://www.zacks.com/stock/news/188031/novo-nordisk-to-start-pioneer-program-on-semaglutide?cid=CS-ZC-FT-188031 Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review http://www.zacks.com/stock/news/188749/bristol-myers-abbvie-cancer-drug-gets-priority-review?cid=CS-ZC-FT-188749 Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.
Novo Nordisk (NVO) Sees Hammer Chart Pattern: Time to Buy? http://www.zacks.com/stock/news/189330/novo-nordisk-nvo-sees-hammer-chart-pattern-time-to-buy?cid=CS-ZC-FT-189330 Sep 09, 2015 - Novo Nordisk (NVO) Sees Hammer Chart Pattern: Time to Buy?
Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3969958-novo-nordisks-nvo-ceo-lars-rebien-sorensen-q1-2016-results-earnings-call-transcript?source=feed_all_articles May 01, 2016 - Novo Nordisk A/S (NYSE:NVO) Q1 2016 Earnings Conference Call April 29, 2016, 07:00 ET Executives Lars Rebien Sorensen - CEO Mads Krogsgaard Thomsen - Chief Science Officer Jesper Brandgaard - CFO Jako
Novo Nordisk A/S (NVO) Lars Rebien Sørensen on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3996583-novo-nordisk-s-nvo-lars-rebien-sorensen-q2-2016-results-earnings-call-transcript?source=feed_sector_healthcare Aug 05, 2016 - Novo Nordisk A/S (NYSE:NVO)Q2 2016 Earnings CallAugust 05, 2016 7:00 am ETExecutivesLars Rebien Sørensen - President & Chief Executive OfficerMads Krogsgaard Thomsen - Chief Science Officer & Executiv
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA http://www.zacks.com/stock/news/252113/merck-pfizers-diabetes-drug-accepted-for-review-by-fda-ema?cid=CS-ZC-FT-252113 Mar 08, 2017 - Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International http://www.zacks.com/stock/news/251359/zacks-industry-outlook-highlights-sanofi-astrazeneca-novo-nordisk-gilead-sciences-and-valeant-pharmaceuticals-international?cid=CS-ZC-FT-251359 Mar 02, 2017 - Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

Pages: 12345678910...17

<<<Page 5>